Testing a new combination treatment for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that has spread or cannot be removed by surgery.
- Your cancer has been tested for HER2 (a protein) and fits into a specific group like HER2-low, HER2-positive, or triple-negative.
- You have at least one tumor that can be measured on scans.
- Your heart function is good, with an ejection fraction of 55% or higher.
- You have not had certain prior treatments, like a drug called trastuzumab deruxtecan or an antibody that targets both PD-L1 and VEGF.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
This trial tests a new drug called BNT317 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if BNT317 is safe and if it can help shrink tumors.
Hear when a new Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.